Bayer rolls out big changes; 2024’s biotech IPO queue; Dupixent’s ‘next big thing’; 23andMe’s struggle with dual identity; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

We got one short week…
Click here to view original post